BioGaia AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOGY research report →
About the company
BioGaia AB (publ) is a global enterprise dedicated to the development, marketing, and sale of probiotic products, all backed by documented health benefits. The company organizes its activities into three primary divisions: Pediatrics, Adult Health, and 'Other'. Within the Pediatric segment, BioGaia provides items such as liquid drops, oral rehydration solutions, and gut health tablets, alongside supplying probiotic cultures for integration into infant formula.
- CEO
- Theresa Agnew
- IPO
- 2021
- Employees
- 224
- HQ
- Stockholm, SE
Price Chart
- Market Cap
- $1.11B
- P/E
- 36.57
- P/S
- 7.65
- P/B
- 8.65
- EV/EBITDA
- 24.13
- Div Yield
- 3.33%
- Gross Margin
- 72.97%
- Op Margin
- 27.22%
- Net Margin
- 21.49%
- ROE
- 26.09%
- ROIC
- 23.23%
- Revenue
- $1.54B · 8.11%
- Net Income
- $332.76M · -5.30%
- EPS
- $3.29 · -5.46%
- Op Income
- $412.47M
- FCF YoY
- -15.62%
- 52W High
- $11.46
- 52W Low
- $8.79
- 50D MA
- $10.75
- 200D MA
- $10.17
- Beta
- 0.32
- Avg Volume
- 49
Get TickerSpark's AI analysis on BIOGY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BIOGY coverage
Recent articles, reports, and earnings notes.
No research on BIOGY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOGY report →Similar companies
Peers in the same neighborhood.